Barclays PLC Grows Position in Arcus Biosciences, Inc ... - MarketBeat

Dec 28, 2024 · Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with …

0%
OFF

Barclays PLC Grows Position In Arcus Biosciences, Inc ... - MarketBeat

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with …

marketbeat.com

0%
OFF

Barclays PLC Grows Position In Arcus Biosciences, Inc. (NYSE:RCUS)

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with …

defenseworld.net

0%
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased By Barclays …

2 weeks from now

Dec 28, 2024 · Barclays PLC raised its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 49.0% during the third quarter, according to its most recent 13F filing with the …

americanbankingnews.com

0%
OFF

Robert C. Goeltz II Sells 3,594 Shares Of Arcus Biosciences, Inc.

2 weeks from now

Jan 3, 2025 · Barclays PLC raised its position in shares of Arcus Biosciences by 49.0% in the 3rd quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 …

marketbeat.com

0%
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating

2 weeks from now

Dec 27, 2024 · Barclays PLC lifted its position in Arcus Biosciences by 49.0% during the third quarter. Barclays PLC now owns 118,693 shares of the company's stock valued at $1,816,000 …

marketbeat.com

0%
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $34.00 Consensus …

2 weeks from now

Dec 30, 2024 · Barclays PLC grew its stake in Arcus Biosciences by 49.0% during the 3rd quarter. Barclays PLC now owns 118,693 shares of the company’s stock worth $1,816,000 …

americanbankingnews.com

$25.00
OFF

Barclays Issues A Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

Oct 17, 2024 · Barclays analyst Peter Lawson assigned a Buy rating to Arcus Biosciences (RCUS – Research Report) today and set a price target of $25.00.The company’s shares closed …

businessinsider.com

59%
OFF

Fmr LLC Raises Stock Holdings In Arcus Biosciences, Inc.

2 weeks from now

Dec 7, 2024 · Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm’s quarterly revenue was up 50.0% on a year-over-year basis. …

americanbankingnews.com

$29
OFF

Arcus Biosciences Price Target Raised To $29 From $25 At Barclays

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on...

businessinsider.com

$29
OFF

Arcus Biosciences Price Target Raised To $29 From $25 At Barclays

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha …

nasdaq.com

0%
OFF

Arcus Biosciences (RCUS) News Today - MarketBeat

2 weeks from now

Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 49.0% during the 3rd quarter, according to its most recent disclosure with the Securities …

marketbeat.com

4%
OFF

Vanguard Group Inc. Raises Stock Position In Arcus ... - MarketBeat

2 weeks from now

Aug 5, 2024 · Vanguard Group Inc. lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 2.4% in the first quarter, according to its most recent filing with the Securities …

marketbeat.com

9%
OFF

Barclays PLC Raises Position In Harmony Biosciences ... - MarketBeat

2 weeks from now

Dec 24, 2024 · Barclays PLC raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 110.9% during the 3rd quarter, according to the company …

marketbeat.com

9%
OFF

Barclays PLC Boosts Holdings In Tarsus Pharmaceuticals

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the third quarter, according to the company in its most recent …

marketbeat.com

FAQs about Barclays PLC Grows Position in Arcus Biosciences, Inc ... - MarketBeat Coupon?

Does Lawson buy Arcus Biosciences (Arcus)?

Lawson covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Syndax Pharmaceuticals, and Arcus Biosciences. In addition to Barclays, Arcus Biosciences also received a Buy from Wells Fargo’s Eva Fortea Verdejo in a report issued on October 8. ...

How did Arcus Biosciences perform compared to last year?

Based on Arcus Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $39 million and a GAAP net loss of $93 million. In comparison, last year the company earned a revenue of $29 million and had a GAAP net loss of $75 million ...

Is Barclays a good investment bank?

Steady global growth has resulted in a solid macro backdrop, but there are concerning developments below the surface according to our Research analysts. Barclays is a British universal bank. Our businesses include consumer banking, as well as a top-tier, global corporate and investment bank. ...